ArticleThe Journal of cell biology1999
CD38/ADP-ribosyl cyclase: A new role in the regulation of osteoclastic bone resorption.
Article in The Journal of cell biology, 1999. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 79 citations in OpenAlex.
- CD38 defines a therapeutically targetable pathogenic T cell population for precision immunotherapy in autoimmune diabetes.bioRxiv : the preprint server for biology · 2026Article
- Article
- Genome-wide association study for bone quality of ducks during the laying period.Poultry science · 2024Article
- Uncovering Hidden Mechanisms of Different Prescriptions Treatment for OsteoporosisFrontiers in cell and developmental biology · 2022Article
- Review
- NADH/NADBiomolecules · 2021Review
- Review
- New mechanisms of phenytoin in calcium homeostasis: competitive inhibition of CD38 in hippocampal cells.Daru : journal of Faculty of Pharmacy, Tehran University of Medical Sciences · 2018Article
- Probing the requirement for CD38 in retinoic acid-induced HL-60 cell differentiation with a small molecule dimerizer and genetic knockout.Scientific reports · 2017Article
- Expression of CD38 in myeloma bone niche: A rational basis for the use of anti-CD38 immunotherapy to inhibit osteoclast formation.Oncotarget · 2017Article
- Monoclonal antibodies targeting CD38 in hematological malignancies and beyond.Immunological reviews · 2016Review
- Effects of NAD at purine receptors in isolated blood vessels.Purinergic signalling · 2015Article
- The role of calcium and nicotinic acid adenine dinucleotide phosphate (NAADP) in human osteoclast formation and resorption.Calcified tissue international · 2015Article
- Gene-set based genome-wide association analysis for the speed of sound in two skeletal sites of Korean women.BMB reports · 2014Article
- E proteins regulate osteoclast maturation and survival.Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research · 2012Article
- Involvement of P2X receptors in the NAD(+)-induced rise in [Ca (2+)] (i) in human monocytes.Purinergic signalling · 2009Article
- Calcium signalling and calcium transport in bone disease.Sub-cellular biochemistry · 2007Review
- Invited Lectures : Overviews Purinergic signalling: past, present and future.Purinergic signalling · 2006Article
- CD38 is associated with premenopausal and postmenopausal bone mineral density and postmenopausal bone loss.Journal of bone and mineral metabolism · 2006Article
- Calcineurin regulates bone formation by the osteoblast.Proceedings of the National Academy of Sciences of the United States of America · 2005Article
Corrections and comments
- Erratum issued
Authors and funding
17 authors at 2 institutions in 2 countries.
Funding
Abstract
The multifunctional ADP-ribosyl cyclase, CD38, catalyzes the cyclization of NAD(+) to cyclic ADP-ribose (cADPr). The latter gates Ca(2+) release through microsomal membrane-resident ryanodine receptors (RyRs). We first cloned and sequenced full-length CD38 cDNA from a rabbit osteoclast cDNA library. The predicted amino acid sequence displayed 59, 59, and 50% similarity, respectively, to the mouse, rat, and human CD38. In situ RT-PCR revealed intense cytoplasmic staining of osteoclasts, confirming CD38 mRNA expression. Both confocal microscopy and Western blotting confirmed the plasma membrane localization of the CD38 protein. The ADP-ribosyl cyclase activity of osteoclastic CD38 was next demonstrated by its ability to cyclize the NAD(+) surrogate, NGD(+), to its fluorescent derivative cGDP-ribose. We then examined the effects of CD38 on osteoclast function. CD38 activation by an agonist antibody (A10) in the presence of substrate (NAD(+)) triggered a cytosolic Ca(2+) signal. Both ryanodine receptor modulators, ryanodine, and caffeine, markedly attenuated this cytosolic Ca(2+) change. Furthermore, the anti-CD38 agonist antibody expectedly inhibited bone resorption in the pit assay and elevated interleukin-6 (IL-6) secretion. IL-6, in turn, enhanced CD38 mRNA expression. Taken together, the results provide compelling evidence for a new role for CD38/ADP-ribosyl cyclase in the control of bone resorption, most likely exerted via cADPr.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.